A Phase 2 trial of evorpacept plus rituximab and lenalidomide (R2) in patients with untreated indolent non-Hodgkin lymphoma (iNHL) showed a 92% complete response rate, surpassing the historical 50% rate for R2 alone. The combination was well-tolerated and demonstrated significant anti-tumor activity in frontline treatment. Longer follow-up will assess minimal residual disease eradication. ALX Oncology presented positive data at the ASH Annual Meeting 2025, indicating the potential of evorpacept to enhance standard treatments and improve outcomes for patients with iNHL. The trial, led by Dr. Paolo Strati, enrolled 24 patients and achieved a 100% overall response rate with high CR and survival rates.

Read more at GlobeNewswire: ALX Oncology Announces Positive Results from Ongoing